Pacific Edge's revenue climbs, US future still uncertain

Pacific Edge's revenue climbs, US future still uncertain
Very strong revenue growth, but profit still some distance away (Image: Pacific Edge)
Ella Somers
A boom in Pacific Edge’s Cxbladder test sales boosted the firm’s operating revenue soar by 71%, with a helping hand from favourable exchange rates.Chief executive Peter Meintjes said the 2023 financial year had been a year of “enormous change and achievement” for the cancer diagnostic company.“Pacific Edge is geared for growth,” he told the NZX.Operating revenue for the twelve months to March 31 rose $19.6 million, up from $11.4m in the previous year while total revenue jumped 88% to $26.1m.The revenue climb...

More Markets

Infratil's renewables stake drops by US$133m
Markets

Infratil's renewables stake drops by US$133m

Infratil provided updated valuations on three investments.

NZME board spill support builds towards 50%
Markets

NZME board spill support builds towards 50%

An update to the NZX says more shareholders are expressing support for board changes.

Tech titans eye NZ's new golden visas
Policy

Tech titans eye NZ's new golden visas

Investors with tens of millions were 'priced out of the market'. Not any more.

US insurance brokerage buys NZ firm RMA General
Markets

US insurance brokerage buys NZ firm RMA General

New owner Arthur J Gallagher & Co has a market cap of NZ$150 billion.